Can Chemo Cause Tinnitus and What You Can Do About It

Chemotherapy can absolutely cause tinnitus, and platinum-based drugs are the main culprits. In a large prospective study, cisplatin raised the risk of developing new tinnitus by more than five times compared to non-ototoxic medications, while carboplatin roughly quadrupled it. The ringing, buzzing, or hissing that patients describe is not imaginary or incidental; it is a documented side effect of drugs that are among the most effective cancer treatments available, and the gap between how common this problem is and how often patients hear about it before treatment remains uncomfortably wide.

Which Drugs Carry the Highest Risk

Out of more than 700 chemotherapy agents documented in various databases, only about seven are known to cause hearing damage, and two of those, both platinum-based compounds, account for the vast majority of cases.¹ Cisplatin is the worst offender. In the large prospective study mentioned above, cisplatin elevated the risk of new tinnitus by 5.53 times, while carboplatin came in at 3.75 times, both compared to patients on drugs that are not considered ototoxic.² Taxanes, another class of chemotherapy drugs, also appear to contribute. A study comparing survivors who received a platinum drug alone, a taxane alone, or both found tinnitus rates of roughly 37 to 40 percent across all three groups, with no statistically significant difference among them. That finding suggests overlapping damage pathways rather than a problem unique to one drug family.³

Ototoxicity as a broader category, which includes both measurable hearing loss and tinnitus, has been reported in up to 80 percent of patients receiving platinum-based chemotherapy.⁴ In children, some estimates push even higher, with one review noting that platinum drugs cause ototoxic hearing loss in nearly all cases when high-frequency ranges are included in testing.⁵ The distinction between hearing loss and tinnitus matters here: you can have measurable hearing damage without perceiving a ringing sound, and you can experience tinnitus even when a standard hearing test looks relatively normal. They are related but not identical problems.

How Platinum Drugs Damage the Inner Ear

The inner ear contains tiny sensory cells called outer hair cells that amplify sound vibrations before they reach the nerve fibers that carry signals to the brain. Platinum compounds, especially cisplatin, are toxic to these cells. They accumulate in the fluid-filled chambers of the inner ear and trigger cell death, starting in the base of the cochlea, which is the region responsible for processing high-frequency sounds. That is why the earliest hearing changes from chemotherapy almost always show up at high pitches before affecting the speech-frequency range.

Animal research has shown what happens in the brain after that damage occurs. When outer hair cells in the base of the cochlea are destroyed, neurons in a part of the brainstem called the dorsal cochlear nucleus become abnormally hyperactive. In one study, about 75 percent of cisplatin-treated animals with severe outer hair cell loss developed this hyperactivity, concentrated in the high-frequency region of the nucleus, matching the pattern of hair cell destruction. Animals with little or no hair cell loss showed no such change.⁶ Think of it as the brain turning up its own volume to compensate for missing input and, in the process, generating a phantom signal that you perceive as ringing or buzzing. The hyperactivity is the neural correlate of tinnitus, and it appears to be triggered specifically by the loss of the amplifying function that outer hair cells normally provide.

Who Faces the Highest Risk

Cumulative dose is the single most consistent risk factor. In a study of testicular cancer survivors treated with cisplatin, tinnitus risk climbed steadily with total dose. Survivors who received more than 400 mg/m² had roughly 2.6 times the risk of those who received 400 or less.⁷ A separate analysis of testicular cancer survivors found that cumulative cisplatin dose was a powerful predictor of tinnitus, alongside age at the time of the survey.⁸

Age cuts both ways depending on the population. In adults, older age at diagnosis and older age at the time of evaluation both increase tinnitus risk.⁷ In children, younger age at treatment is actually the stronger risk factor for hearing damage, and cranial radiation on top of chemotherapy compounds the problem substantially.⁵ A Swiss study of childhood cancer survivors found that treatment with cisplatin carried an odds ratio of 9.4 for self-reported hearing loss, while carboplatin had an odds ratio of 2.4. High-dose cranial radiation and brain surgery each added independent risk.⁹

Existing cardiovascular risk factors may also play a role. Testicular cancer survivors with tinnitus were more likely to report high cholesterol than those without it.⁸ The connection probably involves blood supply to the cochlea, which is sensitive to vascular health, though the evidence on this is still circumstantial.

When Tinnitus Appears and Whether It Goes Away

Tinnitus can begin during the first cycle of chemotherapy, show up weeks after treatment ends, or emerge months to years later. A systematic review of childhood cancer studies found that the relative risk of developing tinnitus was highest during active therapy, at up to about 17 times the risk compared to siblings, but remained elevated at roughly 3.7 times baseline even more than five years after diagnosis.¹⁰ The delayed cases are particularly unsettling because patients may have assumed they escaped the side effect, only to have it surface well into survivorship.

For many people, chemotherapy-induced tinnitus is permanent. In a qualitative study that analyzed patient posts across online health forums, 71 percent of those who reported how long their tinnitus lasted described it as permanent.¹¹ That number should be interpreted carefully, since people whose tinnitus resolved quickly may be less motivated to post about it online, potentially skewing the sample toward more persistent cases. Still, the underlying biology supports the concern: when outer hair cells die, they do not regenerate in humans, and the neural changes that follow can become self-sustaining. Tinnitus from platinum drugs can also be either reversible or irreversible depending on the severity and extent of damage.¹² Mild cases sometimes fade after treatment stops, but there is no reliable way to predict ahead of time who will be in the lucky group.

The Broader Impact on Daily Life

Tinnitus is often framed as a minor annoyance, but for cancer survivors it can be genuinely disabling. Survivors with cisplatin-induced tinnitus report significantly worse hearing across all frequencies, more difficulty understanding speech in noisy environments, and greater use of psychotropic medications than survivors without it.⁷ They also report more vertigo and poorer overall self-rated health. Depression and anxiety are associated with ototoxicity in the survivorship literature.¹³

Validated questionnaires used in research break tinnitus interference into domains like concentration, emotion, hearing, and sleep. In studies of testicular cancer survivors, these tools show a range from minimal interference to significant impairment, and the severity tends to track with objective measures of hearing loss.¹⁴ The practical upshot is that even when tinnitus does not reach the threshold of “catastrophic,” it can quietly erode quality of life, especially when combined with the fatigue, anxiety, and cognitive changes that already accompany cancer treatment and survivorship.

Why Your Oncologist May Not Bring It Up

One of the more frustrating findings in the research is how inconsistently ototoxicity is discussed before and during treatment. Qualitative interviews with oncologists in India revealed candid admissions: several acknowledged that they simply do not perform baseline audiograms before starting cisplatin, relying instead on asking patients whether their hearing seems normal. One oncologist said outright, “We are not stressing on the ototoxicity because usually it happens at the higher-frequency level.”¹⁵ Another admitted they had never referred anyone to an audiologist for hearing assessment during treatment.

A study surveying institutional practices in Saudi Arabia found similar gaps: adult referrals for audiological monitoring were rare, pediatric monitoring was inconsistent, and long-term follow-up was limited, even within the same hospital.¹⁶ This is not a developing-world-only problem. Ototoxicity monitoring guidelines exist, but adherence varies widely across institutions in all countries. The result is that many patients do not learn their hearing has changed until the damage is already advanced enough to affect everyday conversation.

Catching Damage Early With the Right Tests

Standard hearing tests check frequencies up to about 8,000 Hz, which covers the speech range. But platinum drugs tend to hit the very high frequencies first, sometimes well above 8,000 Hz, before working their way down. Extended high-frequency audiometry, which tests up to 16,000 Hz or beyond, can pick up ototoxic changes before they show on a conventional test. Pilot data in children undergoing platinum chemotherapy showed that extended high-frequency testing and a measurement called distortion-product otoacoustic emissions both detected shifts earlier than standard audiometry.¹⁷

This matters because early detection creates options. If a baseline test is done before chemotherapy starts and repeated between cycles, a significant threshold shift can prompt a conversation about adjusting the treatment plan, switching drugs, or modifying dosing before the hearing loss extends into ranges that affect speech comprehension. Without that baseline, you are left comparing the patient’s current hearing to population averages, which is far less sensitive. If you are about to start platinum-based chemotherapy, asking for a baseline audiogram is one of the most concrete things you can do. It costs little, takes under an hour, and gives your care team a reference point that could change decisions down the road.

What Can Actually Be Done About It

Managing chemotherapy-induced tinnitus involves two broad strategies: preventing it in the first place and reducing its impact once it exists.

Dosing Adjustments

One approach gaining evidence is changing how cisplatin is delivered. A study comparing weekly low-dose cisplatin to the traditional once-every-three-weeks high-dose schedule in head and neck cancer patients found that two-year survival and disease-free survival were comparable between the two approaches, but the lower, more frequent dosing was associated with less hearing damage.¹⁸ The logic is straightforward: the inner ear’s vulnerability to cisplatin depends heavily on peak drug concentration, so spreading the same total dose across smaller individual hits reduces the spike that does the most damage. This is a conversation worth having with your oncologist, though the decision always involves weighing ear toxicity against cancer-treatment effectiveness for your specific situation.

Cognitive Behavioral Therapy

Once tinnitus is present, no pill reliably eliminates it. The treatment with the strongest evidence base for reducing the suffering it causes is cognitive behavioral therapy, or CBT. CBT for tinnitus does not aim to make the sound disappear. Instead, it targets the cycle of negative thoughts, attention, and emotional distress that makes tinnitus feel unbearable. By helping patients reframe their reaction to the sound and develop coping strategies, it can substantially reduce how much tinnitus interferes with sleep, concentration, and mood.¹⁹ Sound therapy, white noise generators, hearing aids (when there is coexisting hearing loss), and mindfulness-based approaches can also help, though the evidence for each varies. The key insight is that tinnitus severity, in terms of how much it disrupts your life, is surprisingly separable from tinnitus loudness. People with the same measured sound level can have vastly different levels of distress, and that gap is where treatment works.

Experimental Protectants Under Investigation

Researchers have been searching for drugs that can shield the inner ear from cisplatin damage without interfering with its cancer-killing ability. Two of the most studied candidates involve delivering protective agents directly through the eardrum into the middle ear, bypassing the bloodstream entirely.

Intratympanic dexamethasone, a steroid injected through the eardrum, has shown promise in animal models. Human trials are still in early stages, and the results so far have been mixed. A phase 2 trial in children tested a sustained-release dexamethasone gel (OTO-104) injected into the middle ear alongside cisplatin treatment. The gel was safe and the procedure was feasible, but at the dose tested, it did not provide clear hearing protection.²⁰ The researchers concluded that the delivery method itself works and could be used to test other protective agents in the future.²¹

Sodium thiosulfate, a chemical that neutralizes cisplatin, has been tested in both intravenous and local forms. A randomized trial explored trans-tympanic injection of a sodium thiosulfate gel in head and neck cancer patients receiving cisplatin. The gel appeared safe for the middle and inner ear, but the researchers noted that more work is needed to improve how well it actually prevents hearing damage.²² The challenge with all these approaches is getting enough protectant to the right cells at the right time without reducing the drug’s effectiveness against the tumor. That balance has not been cracked yet, but the delivery technology is advancing.

Genetics and the Uneven Playing Field

Not everyone who receives the same dose of cisplatin develops tinnitus, which has long suggested a genetic component. A genome-wide analysis comparing cancer-treatment-related tinnitus to tinnitus in the general population found something striking: the genetic risk factors were largely distinct between the two groups. Of 101 genetic variants linked to tinnitus in a large general-population database, only one replicated in a study of cancer survivors, a variant in the gene encoding PD-L1, a protein better known for its role in immune regulation.²³ The implication is that chemotherapy-induced tinnitus may involve different biological pathways than the tinnitus people develop from aging or noise exposure. If that holds up, it means treatments developed for garden-variety tinnitus may not directly apply, and prevention strategies might need to be tailored to the specific damage cisplatin causes.

Pharmacogenomic testing, the idea that a genetic profile could predict who is most vulnerable before treatment starts, is still in early research phases for ototoxicity. But the concept is appealing. If a simple blood test could identify patients at very high risk for permanent tinnitus, oncologists could factor that into decisions about dosing, drug choice, and monitoring intensity. The science is not there yet in a clinically actionable sense, but the groundwork is being laid.

Practical Steps If You Are Facing Platinum Chemotherapy

If you or someone you care about is about to start cisplatin, carboplatin, or a combination that includes either drug, there are concrete actions worth taking. Request a baseline audiogram before the first cycle, and ask that it include extended high-frequency testing if the facility can provide it. Bring up tinnitus monitoring at your treatment planning appointment rather than waiting for your oncologist to mention it, because the evidence suggests many will not.¹⁵ If you develop ringing or a change in hearing at any point during or after treatment, report it immediately rather than assuming it will pass. Early detection during treatment can sometimes lead to dose modifications or drug switches that prevent further damage.

After treatment, continue to pay attention to your hearing. The delayed-onset pattern seen in both adults and children means that audiological follow-up should not stop when chemotherapy does.¹⁰ If tinnitus persists and bothers you, ask for a referral to an audiologist who works with tinnitus patients. CBT-based programs, sound therapy, and hearing aids when appropriate can make a real difference in daily functioning, even if the underlying ringing does not change. Protecting whatever hearing you have left by avoiding loud environments and using ear protection in noisy settings is simple advice, but it matters more after ototoxic treatment than it would for someone starting with an undamaged cochlea.